NCT03453489View on ClinicalTrials.gov

AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm

PHASE2CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

June 20, 2018

Primary Completion Date

October 15, 2020

Study Completion Date

October 15, 2020

Conditions
Carcinoid SyndromeMetastatic Nonfunctional Well Differentiated Neuroendocrine Neoplasm
Interventions
OTHER

Carbon C 11 Alpha-methyltryptophan

Undergo AMT-PET

OTHER

Laboratory Biomarker Analysis

Correlative studies

PROCEDURE

Positron Emission Tomography

Undergo AMT-PET

DRUG

Telotristat Etiprate

Given PO

Trial Locations (1)

48201

Wayne State University/Karmanos Cancer Institute, Detroit

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Barbara Ann Karmanos Cancer Institute

OTHER

NCT03453489 - AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm | Biotech Hunter | Biotech Hunter